Exicure Inc. (XCUR)
NASDAQ: XCUR
· Real-Time Price · USD
10.71
0.74 (7.42%)
At close: May 02, 2025, 3:59 PM
10.71
0.00%
After-hours: May 02, 2025, 04:05 PM EDT
7.42% (1D)
| Bid | 10 |
| Market Cap | 67.66M |
| Revenue (ttm) | 500K |
| Net Income (ttm) | -9.7M |
| EPS (ttm) | -4.75 |
| PE Ratio (ttm) | -2.25 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 10.75 |
| Volume | 6,892 |
| Avg. Volume (20D) | 30,735 |
| Open | 10.46 |
| Previous Close | 9.97 |
| Day's Range | 10.00 - 10.73 |
| 52-Week Range | 1.44 - 36.00 |
| Beta | 3.75 |
About XCUR
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S...
Industry Biotechnology
Sector Healthcare
IPO Date May 22, 2018
Employees 7
Stock Exchange NASDAQ
Ticker Symbol XCUR
Website https://www.exicuretx.com
3 months ago
-15.07%
Exicure shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago
+35.86%
Exicure shares are trading higher after the company reported a year-over-year increase in Q3 PES results. Additionally, the company announced it entered into a purchase agreement for $1.3 million and $8.7 million in equity financing.
3 weeks ago · businesswire.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
